Pricing Log in Create free account
Saturday 17 October 2026 Export HYFT’s income statement to Excel — free account

MindWalk Holdings Corp.

HYFT Healthcare Biotechnology

MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025. In the quarter to July 2026, revenue grew 19.4%, EPS fell 80.0%, free cash flow grew 9.79% and total debt fell 10.8%, each against the same quarter a year earlier.

1.31 0.09 −6.43%
Market cap
$66.0M
P/E
0.0×
Fwd P/E
−9.0×
Dividend yield
—
F-score
6/9
Altman Z
−5.59
Beneish M
−3.70
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 8.86%

Capital & Financial Ratios $m

Market Cap 65.95
Revenue 11.72
Net Income (12.31)
Free Cash Flow (9.00)
Net Debt (3.31)
Current Ratio 1.84 (at or above 1.5: strong)
Debt/Equity 0.43 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (9.01) (negative: loss-making)
P/S ratio 5.23
P/B ratio 12.39 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth (24.24%) (below 0%: weak)
Next Y EPS Growth 14.00%
Next Y revenue growth 9.69%
Next 5Y EPS Growth 3.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.1×, against a ten-year median of 5.0×; over the ten years it ranged from 0.7× in 2025 to 20.7× in 2021.
P/S against its own 10 years 48.80%
10-year low 10-year high
P/B against its own 10 years 97.05%
10-year low 10-year high
EV/Sales against its own 10 years 55.82%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 3 8 8 5
Receivables 3 3 2 2
Inventory 2 2 0 0
Other 0 0 0 1
9 13 12 9
2024 2025 2026 Q'26
Payables 3 4 3 4
ST’ Debt — — — —
Other 0 0 — —
6 6 4 5

Compound Annual Growth %

10y 5y 3y
Sales — (3.83%) (10.16%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (27.85%) (41.94%)

Revenue $m

Jul Oct Jan Apr Year
’26 3 — — — —
’26 2 3 3 3 11
’25 4 4 4 5 18
’24 4 5 5 5 18
’23 4 4 4 4 16
’22 4 4 4 4 15
’21 3 4 4 4 14
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jul Oct Jan Apr Year
’26 (3) — — — —
’26 (3) (2) (2) (2) (9)
’25 (1) (2) (1) (1) (5)
’24 (1) 0 0 (2) (3)
’23 (8) (3) (3) (2) (15)
’22 (1) (2) (4) (1) (8)
’21 0 0 (1) 0 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jul Oct Jan Apr Year
’26 (3) — — — —
’26 (3) (2) (2) (2) (9)
’25 (2) (2) (1) (1) (5)
’24 (1) 0 0 (3) (4)
’23 (8) (3) (3) (2) (16)
’22 (1) (2) (5) (2) (9)
’21 0 0 (1) (2) (2)
Fiscal quarters ending in the months shown.

EPS $

Jul Oct Jan Apr Year
’26 (0.09) — — — —
’26 (0.05) (0.05) (0.06) (0.06) (0.22)
’25 (0.11) (0.07) (0.46) (0.04) (0.65)
’24 (0.11) (0.07) (0.08) (0.52) (0.78)
’23 (0.30) (0.23) (0.14) (0.15) (0.81)
’22 (0.14) (0.21) (0.16) (0.17) (0.67)
’21 (0.03) (0.02) (0.06) (0.23) (0.34)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to April

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 1.88 1.32 1.65 1.15 5.03 3.51 0.94 0.33 0.27 0.99

Analyst estimates 2027–2029

Powerpack
High 5.94 5.05 3.17 33.34 19.00 6.79 5.60 2.60 3.25 2.99
People
People Employees — — — — 73 85 102 101 102 77
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.19 0.18 0.15 0.18 0.17 0.15
Income, $m
Income, $m Revenue 2 3 6 8 14 15 16 18 18 11
Gross margin, % 27.33 (23.62) (16.92) (3.92) 64.41 56.72 55.95 49.16 55.25 58.80
EBT (4) (3) (4) (3) (5) (13) (21) (21) (25) (11)
EBT margin, % (207.80) (93.02) (69.67) (37.65) (33.47) (81.84) (134.29) (117.07) (139.75) (99.96)
Net income 0 (3) (4) (3) (6) (13) (20) (20) (22) (10)
Depreciation 0 0 1 2 3 3 5 4 4 1
Per share, $
Per share, $ Revenue 0.49 0.36 0.49 0.56 0.83 0.78 0.62 0.71 0.53 0.24
Earnings (0.99) (0.33) (0.34) (0.19) (0.34) (0.67) (0.81) (0.78) (0.65) (0.22)
Cash flow (0.14) (0.23) (0.14) (0.05) (0.03) (0.40) (0.60) (0.12) (0.14) (0.19)
Capex 0.00 0.00 0.00 0.00 (0.06) (0.05) (0.05) (0.04) (0.02) (0.01)
Free cash flow (0.14) (0.23) (0.14) (0.05) (0.09) (0.45) (0.64) (0.16) (0.15) (0.20)
Book value 0.57 0.84 0.80 0.57 2.64 3.05 1.75 0.98 0.51 0.18
Shares, m 4 9 13 14 16 20 25 26 33 46
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.00 12.29 7.05 4.12 1.81 0.84 4.90
P/B 0.00 0.00 0.00 0.00 3.89 1.81 1.47 1.31 0.87 6.48
EV/Sales 0.00 0.00 0.00 0.00 10.16 5.59 4.05 2.19 1.00 4.56
EV/FCF 0.00 0.00 0.00 0.00 (365.48) (9.86) (3.93) (9.50) (3.40) (5.52)
Cash, $m
Cash, $m Operating cash flow (1) (2) (2) (1) 0 (8) (15) (3) (5) (9)
Capex 0 0 0 0 (1) (1) (1) (1) (1) 0
Free cash flow (1) (2) (2) (1) (2) (9) (16) (4) (5) (9)
Balance, $m
Balance, $m Working capital 2 0 1 0 33 22 8 2 7 8
Total debt — 2 2 2 3 1 5 9 8 2
Net debt (2) 1 (1) 1 (29) (23) (2) 6 1 (6)
Shareholders’ equity 2 8 10 8 44 60 43 25 17 9
Returns, %
Returns, % ROA (61,796.48) (42.17) (28.16) (17.81) (17.19) (21.18) (30.03) (39.09) (56.85) (42.67)
ROIC 0.00 0.00 0.00 0.00 (23.94) (21.62) (32.05) (20.69) (31.55) (269.05)
ROE (381.82) (63.01) (48.75) (29.87) (21.87) (25.72) (38.62) (58.67) (103.12) (79.38)
Negative figures in brackets.

All 10 years →

Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

MindWalk Holdings Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CSBR Champions Oncology, Inc. $66.7M — (loss-making) — (loss-making) +8.84% (above 0%: growing) n/m −198.74% (below 0%: shrinking) 50.54% (2.69%) Compare
OSTX OS Therapies Incorporated $66.0M — (loss-making) — — n/m −134.43% (below 0%: shrinking) — 0.00% Compare
HYFT MindWalk Holdings Corp. $66.0M — (loss-making) — (loss-making) +19.37% (above 0%: growing) n/m +9.79% (above 0%: growing) 58.58% (159.86%)
NMAD Nomad Power Solutions, Inc. $65.9M — (loss-making) — — n/m −230.63% (below 0%: shrinking) — 0.00% Compare
XBIT XBiotech Inc. $65.9M — (loss-making) — (loss-making) −93.33% (below 0%: shrinking) n/m +25.25% (above 0%: growing) 0.00% 0.00% Compare
SPRO Spero Therapeutics, Inc. $65.8M 7.9× 4.2× −95.61% (below 0%: shrinking) n/m +69.73% (above 0%: growing) 100.00% 0.00% Compare
VRCA Verrica Pharmaceuticals Inc. $64.9M — (loss-making) — (loss-making) −53.85% (below 0%: shrinking) n/m +7.63% (above 0%: growing) 85.02% (223.42%) Compare
CING Cingulate Inc. $63.8M — (loss-making) — — n/m −24.28% (below 0%: shrinking) 0.00% 0.00% Compare
FBIO Fortress Biotech, Inc. $63.7M 0.6× 1.1× +14.04% (above 0%: growing) n/m −115.37% (below 0%: shrinking) 67.18% (53.46%) Compare
Median of peers $65.8M — — −53.85% — −69.82% 58.86% 0.00%

All 614 Biotechnology stocks →

MindWalk Holdings Corp. (HYFT) key facts

  • Concern: MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025.
  • Concern: MindWalk Holdings Corp. reported a net loss of $10.1 million, or a loss of $0.22 per share, for fiscal 2026.
  • MindWalk Holdings Corp. (HYFT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, HYFT traded at $1.31, a market capitalization of $66.0 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 5.2× sales.
  • Return on equity was −79.4% and debt-to-equity 0.43.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −5.59 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.

MindWalk Holdings Corp. (HYFT) Latest News

5 Jun

Impact 5 ·
stockrow.com/HYFT · Data as of Oct 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com